NCT06615700View on ClinicalTrials.gov

Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

May 6, 2024

Primary Completion Date

August 12, 2024

Study Completion Date

September 20, 2024

Conditions
Overweight or ObesityType 2 Diabetes
Interventions
DRUG

NA-931

NA-931 is a quadruple receptor agonist for weight loss

DRUG

Placebo

Placebo of NA-931

Trial Locations (2)

2050

Biomed Industries Pty Limited- Clinical Testing Site 1, Camperdown

3052

Biomed Industries, Pty Limited Testing Site 2, Parkville

All Listed Sponsors
lead

Biomed Industries, Inc.

INDUSTRY

NCT06615700 - Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter